Pfizer pays $179m for Brisbane company behind smartphone app that claims to diagnose COVID
A Brisbane-based company that invented a smartphone app it says can diagnose COVID-19 and other respiratory illnesses by listening to someone cough has been purchased by Pfizer for nearly $180 million.
ResApp Health Limited uses diagnostic technology developed by Associate Professor Udantha Abeyratne and his research team at the University of Queensland (UQ) to record and analyse a patient's coughs on a smartphone.
The app also considers the self-reporting of simple symptoms like a runny nose or fever to diagnose and measure the severity of a range of pulmonary diseases, including asthma and pneumonia.
Read More: https://www.abc.net.au/news/2022-09-28/qld-pfizer-buys-uq-start-upresapp-health-covid/101478832
Comments
Post a Comment